Abstract
Using subtractive hybridization techniques, we have isolated a gene termed JAC that is strongly and specifically activated in avian fibroblasts transformed by the v-jun oncogene of avian sarcoma virus 17 (ASV17), but not in cells transformed by other oncogenic agents. Furthermore, JAC is highly expressed in cell lines derived from jun-induced avian fibrosarcomas. Kinetic analysis using a doxycycline-controlled conditional cell transformation system showed that expression of the 0.8-kb JAC mRNA is induced rapidly upon activation of the oncogenic v-jun allele. Nucleotide sequence analysis and transcriptional mapping revealed that the JAC gene contains two exons, with the longest ORF confined to exon 2. The deduced 68-amino acid chicken JAC protein is rich in cysteine residues and displays 37% sequence identity to mammalian high-sulfur keratin-associated proteins. The promoter region of JAC contains a consensus (5′-TGACTCA-3′) and a nonconsensus (5′-TGAGTAA-3′) AP-1 binding site in tandem, which are both specifically bound by the Gag-Jun hybrid protein encoded by ASV17. Mutational analysis revealed that the two AP-1 sites confer strong transcriptional activation by Gag-Jun in a synergistic manner. Ectopic expression of JAC in avian fibroblasts leads to anchorage-independent growth, strongly suggesting that deregulation of JAC is an essential event in jun-induced cell transformation and tumorigenesis.
Keywords: jun oncogene‖signal transduction‖gene expression‖protein–DNA interaction‖transcriptional control
The v-jun oncogene was originally identified as the transforming principle of avian sarcoma virus 17 (ASV17) (1). Expression of v-jun leads to transformation of avian fibroblasts (2) and to induction of fibrosarcomas in chicken (2, 3). The cellular progenitor of the retroviral v-jun oncogene, the c-jun protooncogene (4), encodes a major component of the transcription factor complex AP-1, which represents a collection of dimers consisting of Jun, Fos, or ATF protein family members (2, 5–7). Gene regulation by AP-1 is important for cell proliferation and differentiation, particularly during epidermal development (8), but constitutive AP-1 activation can lead to tumor formation (2, 6–8). Distinct AP-1-regulated keratin genes are consistently overexpressed in various carcinomas (9), and the transactivation function of AP-1 is required for tumor promotion in epidermal cells (10). Dermal fibrosarcomas have been observed in v-jun transgenic mice upon wounding (11), and the c-fos protooncogene is required for malignant progression of skin tumors (12).
Jun proteins can bind to DNA as functional homodimers, or as heterodimers with Fos or ATF proteins. Jun-Jun and Jun-Fos dimers bind preferentially with high affinity to enhancer elements with the consensus sequence 5′-TGAC/GTCA-3′ located in various AP-1-responsive genes (6, 7), but nonconsensus binding motifs differing in single nucleotides have also been identified (13, 14). There is increasing evidence that cellular transformation induced by the v-Jun protein involves the aberrant expression of specific genes that are normally regulated by endogenous c-Jun as a component of AP-1. Approaches aimed at the identification of genes specifically deregulated in jun- or fos-transformed fibroblasts have led to the identification of several jun target genes (2, 7, 15), including the direct transcriptional targets BKJ, encoding a β-keratin-related protein (16, 17), glutaredoxin (18), the gene encoding heparin-binding epidermal growth factor-like growth factor (HB-EGF) (19), and the TOJ3 gene encoding a protein highly related to microspherule protein 1 (MCRS1) (20). Remarkably, the HB-EGF and TOJ3 genes were shown to induce partial cell transformation when expressed in a retroviral context (19, 20).
Here, we describe the isolation of a jun target gene, termed JAC, that is highly expressed in v-jun-transformed fibroblasts and in v-jun-induced fibrosarcomas, and that is directly and specifically regulated by oncogenic Jun proteins at the transcriptional level. Ectopic expression of JAC in avian fibroblasts leads to anchorage-independent growth, strongly suggesting that deregulation of JAC is an essential event in jun-induced cell transformation and tumorigenesis.
Materials and Methods
Cells and Retroviruses.
Cell culture and transformation of chicken or quail embryo fibroblasts (CEF, QEF) was performed as described (16, 17, 21, 22). Avian retroviruses used were ASV17 (1), NK24 (23), MC29 (22, 24), MH2A10 (25), and Rous sarcoma virus (RSV) (26). For generation of the tumor cell cultures T-ASV17 and T-RCAS-vJun, viral stocks of ASV17 or virus released from Rcas-vJun-transfected CEF, respectively, were injected intravenously into 10-day-old chicken embryos (3). Two months later, fibrosarcomas were recovered and expanded into cell cultures. The quail cell line Q/d3 (21), conditionally transformed by v-jun, and QEF or CEF transformed by the retroviral constructs RCAS-VJ1 and RCAS-VJ0 (27) have been described (16, 17, 21). For construction of DNA templates encoding amino-terminally FLAG-tagged (28) proteins, a double-stranded oligodeoxynucleotide encoding the nine-amino acid peptide tag DYKDDDDKD was inserted between codons 1 and 2 of JAC or HBEGF, respectively. For construction of RCAS-JAC, RCAS-FLAG-JAC, and RCAS-FLAG-HBEGF, the coding regions of chicken JAC and sequences encoding the FLAG-JAC or FLAG-HBEGF fusion proteins were inserted into the RCAS-BP vector (subgroup A) (29), respectively. Colony assays performed in 0.3% (wt/vol) Sea Plaque agarose (BioWhittaker) were done as described (21, 22), using cells 3 weeks after DNA transfection with RCAS constructs.
DNA Cloning and Nucleic Acid Analysis.
Subtracted probe preparation, screening, Northern and Southern analysis, and nucleotide sequencing were performed as described (16, 17). For subtracted probe generation, cDNA synthesized on poly(A)+ RNA from clonal cell cultures derived from ASV17-transformed CEF (17) was hybridized with poly(A)+ RNA from normal CEF. This probe was used to screen a cDNA library derived from ASV17-transformed CEF (17) as described (16) yielding 40 positive phage clones, from which 29 represented the JAC gene. Hybridization probes included the full-length chicken JAC cDNA, the cDNA insert fragments of quail JAC (21), quail BKJ (16), and quail glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (30). For the isolation of JAC genomic clones, a λEMBL3 library of partially MboI-digested chicken genomic DNA was screened as described (17) with 32P-labeled chicken JAC cDNA as a probe.
DNA Binding and Protein Analysis.
Electrophoretic mobility-shift assays were carried out as described (17). The prokaryotic expression vector pET-CV is a derivative of pET-CJ (17) and encodes a chimeric c-Jun/v-Jun protein in which the 168 carboxyl-terminal amino acids of c-Jun (4) are replaced by the homologous 168-amino acid segment of v-Jun (1). This protein was expressed at higher levels in Escherichia coli than the original v-Jun protein (data not shown). Preparation of nuclear extracts from subconfluently grown cells was done as described (31). A 32P-labeled 40-bp double-stranded oligodeoxynucleotide encompassing nucleotide positions 3461–3500 from the JAC promoter region including the AP-1 consensus site 5′-TGACTCA-3′, but excluding the nonconsensus 5′-TGAGTAA-3′ motif, and a mutant oligodeoxynucleotide derivative in which the consensus site is substituted by the sequence 5′-AGACCCA-3′ were prepared as described (17). Binding reactions with nuclear extracts contained 0.25 μg/μl poly(dI-dC)⋅poly(dI-dC). To test binding specificity, polyclonal antisera directed against avian Jun and Fos proteins were added 15 min after the binding reaction was initiated, and incubation was continued for another 15 min. Antisera directed against the amino-terminal 77 amino acids of chicken JunD (32) or against the entire chicken c-Fos protein (33) were prepared analogously as described for the generation of c-Jun/v-Jun or Fra-2-specific antisera (34). Detection of Gag-related proteins has been described previously (17). In vitro transcription/translation reactions using derivatives of pBluescript II SK(+) (Stratagene) as templates was done as described (17). Immunoprecipitation of L-[35S]cysteine-labeled proteins from cell lysates or from in vitro transcription/translation reactions using each 8-μg aliquots of monoclonal Anti-FLAG M2 antibody (Sigma) and SDS/PAGE was done as described (17) with the following modifications. Cells were lysed in a buffer containing 20 mM Tris⋅HCl (pH 8.0), 200 mM LiCl, 1 mM EDTA, 0.5% Nonidet P-40, 2 μg/ml aprotinin, 1 μg/ml leupeptin, and 1 μg/ml pepstatin A, and the lysate was clarified by centrifugation at 20,000 × g. After binding of antigen–antibody complexes to protein A Sepharose CL-4B (Amersham Pharmacia), the solid phase was washed three times in lysis buffer and two times in a buffer containing 20 mM Tris⋅HCl (pH 8.0), 100 mM NaCl, 0.5% Nonidet P-40.
Transactivation Analysis.
For construction of the chloramphenicol acetyltransferase (CAT) reporter plasmid pCAT-JAC, a 725-bp EarI fragment derived from the chicken JAC promoter (p-JAC) was inserted into the polylinker region of pCAT-Basic vector (Promega). For construction of pCAT-JACΔ, a 172-bp SspI–NsiI fragment encompassing both AP-1 binding sites was deleted from pCAT-JAC. Site-directed mutagenesis of AP-1 binding sequences was performed as described (35) with pCAT-JAC or pCAT-JAC-mutD (see below) used as a template, and mutator oligodeoxynucleotides leading to conversion of the distal (D) AP-1 binding site 5′-TGACTCA-3′ into a 5′-AGACCCA-3′ motif (pCAT-JAC-mutD), to deletion of the proximal (P) site 5′-TGAGTAA-3′ (pCAT-JACΔP, pCAT-JAC-mutDΔP), or to deletion of the distal site (pCAT-JACΔD). The reporter construct pCAT-BKJ [pCAT-BKJ(DP)] has been described (17). pRc/RSV (Invitrogen) derived eukaryotic expression vectors used in this study contain the coding regions of the v-jun (1) or v-fos (23) oncogenes fused to partial gag sequences (gag-jun, gag-fos) and derivatives thereof (v-jun, v-fos) lacking the amino-terminal gag portions, of the protooncogenes c-fos (33), fra-2 (36), c-jun (4), junD (32), and of the transforming junD mutant jdv (32). CAT analysis was performed as described (17). Quantification of radioactive signals was done by using a PhosphorImager (Molecular Dynamics).
Results
Specific Expression of JAC in jun-Transformed Avian Fibroblasts.
By using subtractive hybridization cloning of cDNAs, a gene was identified that is specifically activated in CEF transformed by ASV17 (1) carrying the v-jun oncogene. Because of its characteristic expression profile (see below), this gene was termed JAC (for jun-activated gene in CEF). To test for a correlation with jun-induced cell transformation, the expression of JAC was tested in a variety of transformed and nontransformed CEF. Northern analysis using RNAs from CEF transformed by various oncogenes and JAC cDNA as a probe revealed the highly specific expression of a 0.8-kb mRNA in v-jun-transformed cells but not in normal cells or in cells transformed by the v-fos, v-myc, v-myc/v-mil, or v-src oncogenes (Fig. 1A). The activation of JAC was observed at a strikingly high level in all clonal cultures derived from individual ASV17-induced foci of transformed CEF (Fig. 1A). Intriguingly, JAC was also found to be expressed at high levels in cell cultures derived from chicken fibrosarcomas, indicating that JAC is also activated during jun-induced tumorigenesis (Fig. 1B). A conditional quail cell transformation system in which transcription of the ASV17 v-jun allele is controlled by a doxycycline-dependent transactivator (21) was used to determine the kinetics of JAC activation upon conditional induction of oncogenic jun. Fig. 1C shows that both JAC and the direct jun target gene BKJ (16, 17) were fully activated within 3 days following induction of v-jun expression, although the kinetics of the early onsets of induction varied.
Structural Organization of the Chicken JAC Gene.
Nucleotide sequence analysis of various overlapping cDNA clones and of PCR products derived from primer-extended cDNA resulted in the compilation of a full-length 622-bp sequence (GenBank accession no. AF172321), with the longest ORF of 68 codons encoding a putative protein of Mr 7,044 with 18 cysteine residues (26.5%) and an estimated isoelectric point of 7.3 (Fig. 2A). A 564-bp JAC cDNA was also isolated from quail (GenBank accession no. AF172322) encoding a 66-amino acid protein product with 77% sequence identity to the presumed chicken orthologue. Computerized sequence comparison of the chicken JAC amino acid sequence with database entries revealed identities of up to 37% with a large gene family encoding the cysteine-rich human and rodent high-sulfur keratin-associated proteins ranging in their molecular masses from 9.5 to 53.9 kDa and forming part of a rigid matrix in which microfibrils of keratins are embedded (37). To determine the structural organization of the JAC gene, the nucleotide sequence of a 6,758-bp chicken genomic DNA segment (GenBank accession no. AF239161) hybridizing with a JAC cDNA probe was determined (Fig. 2A). The JAC gene contains two exons at positions 3835–3881 and 4315–4889, with the coding region confined to exon 2. Similar to mammalian high-sulfur keratin-associated protein-encoding genes (37), the JAC coding region lacks introns. A TATA box is present 30 bp upstream of the experimentally determined transcriptional start site (data not shown) located at position 3835. Intriguingly, the 5′ upstream region contains one authentic 5′-TGACTCA-3′ heptamer motif for high-affinity AP-1 binding (2, 6, 7) at position 3478–3484 and, only 14 bp further downstream, a nonconsensus AP-1 binding site 5′-TGAGTAA-3′, representing a motif that was identified as a functional element in some AP-1-regulated genes (13, 14). When the 622-bp JAC cDNA probe was used, three EcoRI fragments hybridizing under stringent conditions were detected by Southern analysis of chicken genomic DNA (Fig. 2B). In addition to the expected exon-containing fragments, a 5.6-kbp fragment was detected that contains a 525-bp region with sequences similar to JAC, suggesting that gene duplication may have occurred during evolution of the JAC locus.
Specific Binding of v-Jun to the AP-1 Binding Sites.
To directly demonstrate a specific interaction of v-Jun with the consensus AP-1 binding site present in the JAC promoter, a 40-bp double-stranded oligodeoxynucleotide encompassing this 5′-TGACTCA-3′ motif was used as a DNA probe for electrophoretic mobility-shift analysis. A chimeric recombinant c-Jun/v-Jun protein containing the carboxyl-terminal DNA binding domain from v-Jun bound efficiently to the DNA probe (Fig. 3A). The specificity of the protein–DNA interaction was emphasized by competitive inhibition using the unlabeled DNA probe in excess and by the lack of binding to a corresponding DNA fragment carrying two nucleotide substitutions in the heptamer motif (Fig. 3A). AP-1 binding activity was also detected in nuclear extracts prepared from normal CEF and from the v-jun-transformed tumor cell culture T-ASV17, resulting in the formation of specific protein–DNA complexes (Fig. 3B). To define the nature of these bound proteins, antibodies directed against c-Jun, JunD, c-Fos, Fra-2, or the viral Gag-Jun protein were added to the binding reactions, leading to interference of specific protein–DNA interactions (Fig. 3C) typical for Jun or Fos antibodies (38). In CEF extracts, all known members of the avian cellular Jun and Fos protein families were identified in the protein–DNA complex, with JunD and Fra-2 as the major participants. In T-ASV17 extracts, DNA binding was strongly inhibited by antisera directed against v-Jun/c-Jun or Gag proteins, whereas weak or no interference was observed employing antisera specific for Fra-2, c-Fos, or JunD, respectively (Fig. 3C). Because c-Jun protein is absent in v-jun-transformed cells (17), Gag-Jun, Fra-2, and c-Fos remain as major binding proteins. The additional band migrating below the complex formed by nuclear T-ASV17 proteins could be caused by truncated AP-1 components or result from yet unknown proteins. As representative size markers for protein–DNA complexes formed by nuclear extract proteins, DNA probes complexed with JunD/Fra-2 or Gag-Jun/Fra-2 dimers derived from in vitro translated proteins were applied, which differed in their mobility according to their Mr values (Fig. 3D). Electrophoretic mobility-shift assay analyses using an oligodeoxynucleotide containing the nonconsensus binding site yielded similar results to those described above for binding to the consensus site (data not shown).
Transcriptional Activation of the JAC Promoter by v-Jun.
To determine whether Jun directly activates the chicken JAC promoter, the 5′ upstream region of the JAC gene (p-JAC, compare with Fig. 2A) was tested by CAT analysis. Transactivation of the promoter construct pCAT-JAC (see Fig. 4E) and of the analogous BKJ promoter construct pCAT-BKJ (17) was tested in normal QEF and in QEF infected by ASV17 encoding the Gag-Jun oncoprotein (Fig. 4A). The analysis revealed that Gag-Jun very efficiently transactivated both promoters, whereas in normal QEF only residual CAT activities were observed, apparently because of endogenous AP-1 complexes. To determine the functionality of the AP-1 binding sites present in the JAC promoter, derivatives of pCAT-JAC lacking one or both binding sites, or containing a mutated consensus binding site unable to bind Jun (compare with Fig. 3 A and B), were transiently cotransfected into QEF together with the pRc/RSV-derived expression plasmid encoding Gag-Jun (Fig. 4B). Strong transcriptional activation of the JAC wild-type promoter was detected with Gag-Jun, whereas deletion of the proximal site in addition to mutational inactivation of the distal AP-1 binding site (pCAT-JAC-mutDΔP) led to almost complete suppression of CAT activity, demonstrating the specificity of these Jun-binding motifs. When tested separately, each of the AP-1 binding sites was found to confer transcriptional activation (pCAT-JACΔP, pCAT-JACΔD), albeit at lower levels than the combined sites, indicating a synergistic effect of the tandem organization of the two AP-1 binding sites. The comparison of transcriptional activation potentials of the Gag-Jun (1), Gag-Fos (23), and JDV (32) oncoproteins and of the avian Jun and Fos proteins, c-Jun (4), JunD (32), c-Fos (33), and Fra-2 (36), showed that overexpressed Gag-Jun was the most efficient transactivator of the JAC promoter (Fig. 4C). Interestingly, Fra-2 was the only AP-1 component that did not activate but rather suppressed the JAC promoter when compared with the endogenous AP-1 activity level (Fig. 4C). Analysis of distinct AP-1 dimer combinations composed of overexpressed Jun and Fos proteins showed that only Gag-Jun homodimers, or heterodimers consisting of Gag-Jun/c-Fos or c-Jun/c-Fos, conferred strong transcriptional activation of the entire JAC promoter (Fig. 4D). Because Gag-Jun/Fra-2 heterodimers do not contribute to transcriptional activation of the JAC promoter (Fig. 4D), these results suggest that transactivation in v-jun-transformed cells is mediated either by Gag-Jun/c-Fos heterodimers or by Gag-Jun homodimers.
Overexpressed JAC Induces Cell Transformation.
The strong and specific activation of JAC in v-jun-transformed cells prompted us to test whether overexpression of JAC by itself would adopt some parameters of the transformed phenotype. Hence, the chicken JAC coding sequence was inserted into the replication-competent retroviral RCAS vector (29), and the construct RCAS-JAC was transfected into CEF and QEF. The construct RCAS-HBEGF carrying the transforming jun-target gene HB-EGF (19) was transfected as a control. Transfections of the RCAS-VJ0 or RCAS-VJ1 constructs (27) encoding Gag-Jun or v-Jun proteins, respectively, resulted in full transformation manifested by focus formation after 1 week, whereas no prominent foci were induced by RCAS-JAC. However, when suspended into semisolid medium, cells overexpressing the JAC gene were capable of anchorage-independent growth similar to cells transfected with RCAS-HBEGF (Fig. 5 A and C). Although JAC-induced colonies were smaller in size than colonies derived from cells transformed by the jun oncogene, these results clearly indicate that cells transfected by RCAS-JAC display some of the typical parameters of the transformed state. Expression of JAC from the retroviral construct and ectopic activation of JAC in QEF transformed by RCAS-VJ1 was verified by Northern analysis (Fig. 5B). To monitor protein expression, RCAS-FLAG-JAC and RCAS-FLAG-HBEGF constructs encoding amino-terminal-tagged JAC or HB-EGF proteins were transfected into QEF, leading to colony formation of transformed cells in soft agar (Fig. 5D). The tagged proteins were immunoprecipitated from metabolically labeled lysates by using an antibody directed against the FLAG epitope (Fig. 5E Right). Whereas the overexpressed FLAG-HBEGF with a calculated Mr of 23,651 displayed an apparent Mr of 24,000 in SDS/PAGE, the FLAG-JAC protein with a calculated Mr of 8,154 migrated with an apparent size of ≈15,000. A similar anomalous electrophoretic mobility was also observed for the in vitro translated and immunoprecipitated FLAG-JAC protein (Fig. 5E Left).
Discussion
Oncogenic transcription factors are positioned at the end of known signal transduction cascades converting upstream incoming signals into changes of gene expression (2, 6). To understand the underlying molecular mechanisms leading to neoplastic transformation, the identification and functional characterization of genes aberrantly regulated by oncogenic gene regulators has become an indispensable prerequisite (2, 39, 40). However, the functional dissection of transformation pathways is severely complicated by the increasing evidence that cell transformation apparently involves changes in the expression patterns of multiple genes and even may depend on multiple interactions of transcription factors and coactivators (6, 40–42). Hence, the identification of transformation-relevant target genes acting as effectors downstream of oncogenic transcription factors represents an important step in deciphering this complex network. Several AP-1 target genes have been identified, but the possible role of most of those genes in jun-induced cell transformation has not been assessed yet. However, the recent identification of genes, like BKJ (16, 17), glutaredoxin (18), HB-EGF (19), or JAC, which are directly regulated by Jun and whose expression profiles correlate precisely with the jun-transformed cellular phenotype, strongly supports the hypothesis that cell transformation induced by oncogenic transcription factors is a consequence of aberrant transcriptional regulation of distinct target genes. Based on these criteria, and on its capacity to induce partial cell transformation, the JAC gene described here presumably belongs to the class of genes that are directly involved in jun-induced cell transformation and tumorigenesis.
The structural analysis of the chicken JAC locus revealed the presence of two AP-1 binding sites in the 5′ upstream region. The noncanonical 5′-TGAGTAA-3′ motif has previously been identified as a key regulatory element in the promoter of the AP-1-controlled tissue inhibitor of metalloproteinases-1 gene (Timp-1) (13). Synergistic transcriptional activation by the presence of two AP-1 binding sites in the JAC promoter (compare with Fig. 5) may be explained by their close proximity and may suggest that two bound AP-1 complexes functionally interact with the basal transcription apparatus.
The elucidation of the biochemical function of the JAC protein will be necessary to assess the role of JAC in oncogenesis in molecular terms. Striking features of the predicted JAC protein are the high content of clustered cysteine residues, the aberrant electrophoretic mobility of the ectopically expressed protein, and its relationship to mammalian high-sulfur keratin-associated proteins (37). In analogy to those proteins, the physiological role of JAC could be that of a cytoskeletal matrix protein involved in avian epidermal development.
Because several transformation-relevant jun-target genes have now been identified, it is likely that only the combined action of distinct target gene products will constitute the fully transformed cellular phenotype caused by v-jun. Strong support for this hypothesis comes from the observations that the targets HB-EGF (19) or TOJ3 (20), and the JAC gene described here, have the potential to induce some of the transformation parameters typical for the jun-transformed cellular phenotype. The identification and functional characterization of all relevant jun-target genes, either activated or suppressed, will reveal the molecular mechanisms of the jun-specific transformation program and will also identify possible overlaps with transformation pathways induced by other oncogenic transcription factors.
Acknowledgments
We thank Nicole Meier for excellent technical assistance. K.B. thanks Peter K. Vogt for support during a sabbatical stay at the Scripps Research Institute, La Jolla, CA. This work was supported by Austrian Science Foundation Grant SFB-F002/211 and Austrian National Bank Grant 7357 (to M.H. and K.B.) and by Association pour la Recherche sur le Cancer Grant 9707 (to M.C.).
Abbreviations
- CEF
chicken embryo fibroblasts
- QEF
quail embryo fibroblasts
- CAT
chloramphenicol acetyltransferase
- RSV
Rous sarcoma virus
Footnotes
References
- 1.Maki Y, Bos T J, Davis C, Starbuck M, Vogt P K. Proc Natl Acad Sci USA. 1987;84:2848–2852. doi: 10.1073/pnas.84.9.2848. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Vogt P K. Oncogene. 2001;20:2365–2377. doi: 10.1038/sj.onc.1204443. [DOI] [PubMed] [Google Scholar]
- 3.Jurdic P, Treilleux I, Vandel L, Tabone E, Huguier S, Sergeant A, Castellazzi M. Oncogene. 1995;11:1699–1709. [PubMed] [Google Scholar]
- 4.Nishimura T, Vogt P K. Oncogene. 1988;3:659–663. [PubMed] [Google Scholar]
- 5.Kerr K D, Inoue J, Verma I M. Curr Opin Cell Biol. 1992;4:496–501. doi: 10.1016/0955-0674(92)90017-7. [DOI] [PubMed] [Google Scholar]
- 6.Shaulian E, Karin M. Oncogene. 2001;20:2390–2400. doi: 10.1038/sj.onc.1204383. [DOI] [PubMed] [Google Scholar]
- 7.van Dam H, Castellazzi M. Oncogene. 2001;20:2453–2464. doi: 10.1038/sj.onc.1204239. [DOI] [PubMed] [Google Scholar]
- 8.Angel P, Szabowski A, Schorpp-Kistner M. Oncogene. 2001;20:2413–2423. doi: 10.1038/sj.onc.1204380. [DOI] [PubMed] [Google Scholar]
- 9.Oshima R G, Baribault H, Caulin C. Cancer Metastasis Rev. 1996;15:445–471. doi: 10.1007/BF00054012. [DOI] [PubMed] [Google Scholar]
- 10.Young M R, Li J-J, Rincón M, Flavell R A, Sathyanarayana B K, Hunziker R, Colburn N. Proc Natl Acad Sci USA. 1999;96:9827–9832. doi: 10.1073/pnas.96.17.9827. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Schuh A C, Keating S J, Monteclaro F S, Vogt P K, Breitman M L. Nature (London) 1990;346:756–760. doi: 10.1038/346756a0. [DOI] [PubMed] [Google Scholar]
- 12.Saez E, Rutberg S E, Mueller E, Oppenheim H, Smoluk J, Yuspa S H, Spiegelman B M. Cell. 1995;82:721–732. doi: 10.1016/0092-8674(95)90469-7. [DOI] [PubMed] [Google Scholar]
- 13.Phillips B W, Sharma R, Leco P A, Edwards D R. J Biol Chem. 1999;274:22197–22207. doi: 10.1074/jbc.274.32.22197. [DOI] [PubMed] [Google Scholar]
- 14.Owen R D, Ostrowski M C. Proc Natl Acad Sci USA. 1990;87:3866–3870. doi: 10.1073/pnas.87.10.3866. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Rinehart-Kim J, Johnston M, Birrer M, Bos T. Int J Cancer. 2000;88:180–190. doi: 10.1002/1097-0215(20001015)88:2<180::aid-ijc6>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
- 16.Hartl M, Bister K. Proc Natl Acad Sci USA. 1995;92:11731–11735. doi: 10.1073/pnas.92.25.11731. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Hartl M, Bister K. Oncogene. 1998;17:2901–2913. doi: 10.1038/sj.onc.1202219. [DOI] [PubMed] [Google Scholar]
- 18.Goller M E, Iacovoni J S, Vogt P K, Kruse U. Oncogene. 1998;16:2945–2948. doi: 10.1038/sj.onc.1201819. [DOI] [PubMed] [Google Scholar]
- 19.Fu S, Bottoli I, Goller M, Vogt P K. Proc Natl Acad Sci USA. 1999;96:5716–5721. doi: 10.1073/pnas.96.10.5716. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Bader A G, Schneider M L, Bister K, Hartl M. Oncogene. 2001;20:7524–7535. doi: 10.1038/sj.onc.1204938. [DOI] [PubMed] [Google Scholar]
- 21.Bader A G, Hartl M, Bister K. Virology. 2000;270:98–110. doi: 10.1006/viro.2000.0222. [DOI] [PubMed] [Google Scholar]
- 22.Bister K, Hayman M J, Vogt P K. Virology. 1977;82:431–448. doi: 10.1016/0042-6822(77)90017-4. [DOI] [PubMed] [Google Scholar]
- 23.Nishizawa M, Goto N, Kawai S. J Virol. 1987;61:3733–3740. doi: 10.1128/jvi.61.12.3733-3740.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Tikhonenko A T, Linial M. J Virol. 1992;66:946–955. doi: 10.1128/jvi.66.2.946-955.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Jansen H W, Patschinsky T, Bister K. J Virol. 1983;48:61–73. doi: 10.1128/jvi.48.1.61-73.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Vogt P K. In: Comprehensive Virology. Fraenkel-Conrat H, Wagner R R, editors. Vol. 9. New York: Plenum; 1977. pp. 341–455. [Google Scholar]
- 27.Bos T J, Monteclaro F S, Mitsunobu F, Ball A R, Jr, Chang C H W, Nishimura T, Vogt P K. Genes Dev. 1990;4:1677–1687. doi: 10.1101/gad.4.10.1677. [DOI] [PubMed] [Google Scholar]
- 28.Brizzard B L, Chubet R G, Vizard D L. BioTechniques. 1994;4:730–735. [PubMed] [Google Scholar]
- 29.Petropolous C J, Hughes S H. J Virol. 1991;65:3728–3737. doi: 10.1128/jvi.65.7.3728-3737.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Weiskirchen R, Siemeister G, Hartl M, Bister K. Gene. 1993;128:269–272. doi: 10.1016/0378-1119(93)90573-l. [DOI] [PubMed] [Google Scholar]
- 31.Dignam J D, Lebovitz R M, Roeder R G. Nucleic Acids Res. 1983;11:1475–1489. doi: 10.1093/nar/11.5.1475. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Hartl M, Vogt P K. Cell Growth Differ. 1992;3:909–918. [PubMed] [Google Scholar]
- 33.Mölders H, Jenuwein T, Adamkiewicz J, Müller R. Oncogene. 1987;1:377–385. [PubMed] [Google Scholar]
- 34.Vial E, Perez S, Castellazzi M. Oncogene. 2000;43:5020–5029. doi: 10.1038/sj.onc.1203867. [DOI] [PubMed] [Google Scholar]
- 35.Kloiber K, Weiskirchen R, Kräutler B, Bister K, Konrat R. J Mol Biol. 1999;292:893–908. doi: 10.1006/jmbi.1999.3118. [DOI] [PubMed] [Google Scholar]
- 36.Nishina H, Sato H, Suzuki T, Sato M, Iba H. Proc Natl Acad Sci USA. 1990;87:3619–3623. doi: 10.1073/pnas.87.9.3619. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Rogers M A, Langbein L, Winter H, Ehmann C, Praetzel S, Korn B, Schweizer J. J Biol Chem. 2001;276:19440–19451. doi: 10.1074/jbc.M100657200. [DOI] [PubMed] [Google Scholar]
- 38.Suzuki T, Murakami M, Onai N, Fukuda E, Hashimoto Y, Sonobe M H, Kameda T, Ichinose M, Miki K, Iba H. J Virol. 1994;68:3527–3535. doi: 10.1128/jvi.68.6.3527-3535.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Dang C V. Mol Cell Biol. 1999;19:1–11. doi: 10.1128/mcb.19.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Hanahan D, Weinberg R A. Cell. 2000;100:57–70. doi: 10.1016/s0092-8674(00)81683-9. [DOI] [PubMed] [Google Scholar]
- 41.Mink S, Mutschler B, Weiskirchen R, Bister K, Klempnauer K-H. Proc Natl Acad Sci USA. 1996;93:6635–6640. doi: 10.1073/pnas.93.13.6635. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Eisenman R. Genes Dev. 2001;15:2023–2030. doi: 10.1101/gad928101. [DOI] [PubMed] [Google Scholar]